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The evaluation of drug permeation/penetration of semisolid formulations into animal skin can be useful 
to supplement the pharmaceutical equivalence. This paper describes the in vitro assessment of acyclovir 
(ACV) into porcine skin from commercial formulations with etermination of drug concentration 
in different layers of cutaneous tissue to correlate with effective antiviral concentration in order to 
improve the equivalence decision. Studies were conducted using Franz cells and porcine skin. Selected 
pharmaceutical creams containing ACV had identical (reference and generic) and different (similar) 
excipients. A software program was employed for the simulation of antiviral effectiveness in the skin. 
Regarding ACV skin penetration, the first batch of the generic product showed a significant difference 
from reference and similar products, while in the second batch all products demonstrated equivalent drug 
penetration in the skin. Simulation studies suggest that formulations analysed exhibit a pharmacological 
effect even when in contact with Herpes simplex strains of high IC50 (inhibitory concentration required 
to reduce viral replication by 50%). According to results, it can be assumed that the in vitro cutaneous 
permeation/penetration study does not supply sensitivity information regarding small alterations of 
ACV semisolid formulations due to the variability inherent to the method, although it can be relevant to 
pharmaceutical equivalence studies in the development of semisolid products.
Uniterms: Acyclovir/skin penetration/in vitro studies. Acyclovir/semisolid formulations. Acyclovir/
pharmaceutical equivalence.
INTRODUCTION
A c y c l o v i r  ( 2 - a m i n o - 1 , 9 - d i h y d r o - 9 - ( ( 2 -
hydroxyethoxy)methyl)-6H-purin-6-one) (ACV) (Figure 
1) is a guanosine derivative drug with high specificity 
for herpesviruses. Due to its high efficacy against herpes 
simplex virus (HSV) and varicella-zoster virus, ACV has 
been the leading treatment for these pathologies until now 
(Field, Hodge, 2013). The action mechanism is based on 
competition with endogenous nucleosides for viral DNA 
incorporation, which disable DNA chain elongation and, 
therefore prevent viral replication (Barreca et al., 2003; 
Lupi, Silva, Pereira, 2000).
Regarding the topical dosage forms, currently 
several brands from different manufacturers can be found 
in the market, mainly as cream formulations. It is known 
that to obtain a better effect on skin virus affections, 
antiviral drugs must reach therapeutic concentrations in 
the basal cells of the epidermis, which are the earliest point 
of entry for virus propagation. Accordingly, penetration of 
an active pharmaceutical into the skin is a critical factor 
for successful treatment of oral herpes by ACV topical 
formulation (Hasler-Nguyen et al., 2009).
Implementation of in vitro methods to evaluate 
FIGURE 1 - Chemical structure of ACV.
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the performance of topical pharmaceutical formulations 
is very important, not only to predict drug permeation/
penetration into the skin, but also as a valuable tool to 
compare generic and reference products. Some authors 
also point out its significance to monitor variations 
among batches manufactured on an industrial scale 
(De Paula, Martin, Bentley 2008; Shah et al., 1991). 
Undoubtedly, studies regarding cutaneous penetration/
permeation are important to optimize and develop 
semisolid pharmaceutical formulations. They enable a 
better understanding of what happens to the drug after it 
is applied to the skin, the release from the pharmaceutical 
formulation, penetration and percutaneous absorption.
According to the World Health Organization (WHO, 
2006), studies regarding in vitro cutaneous absorption are 
increasingly being submitted for registration of topical 
products. Several published papers compare in vivo and in 
vitro results, and studies following OECD (Organization 
of Economic Co-operation and Development) directives 
demonstrate that in vitro tests provide a good prediction 
of cutaneous absorption (Alberti et al., 2001; Gannu et al, 
2010; Tsai et al., 2010).
Currently, a release study with Franz vertical 
diffusion cells (VDC) is the in vitro method most 
employed and accepted by international regulation 
guidelines due to its good reproducibility (Sartorelli et al., 
2000; OECD, 2004). FDA (Food and Drug Administration, 
USA) recommends VDC employing synthetic membranes 
to evaluate scale-up and post-approval alteration in 
topical formulations (FDA, 1997). However, cutaneous 
permeation studies employing skin specimens in this 
diffusion bi-compartment model usually provide more 
variable results.
Therefore, the purpose of this paper was to verify 
whether in vitro determination of cutaneous permeation/
penetration of ACV from commercial formulations 
(reference – R, generic – G, and similar – S) can indicate 
the maintenance of drug activity and product equivalence, 
relating the ACV concentration in different layers of 
cutaneous tissue to effective antiviral concentration. A 
bioanalytical method for drug quantification in skin layers 
(epidermis and dermis) of pig ears was validated for this 
purpose.
MATERIAL AND METHODS
Generic and similar 5% ACV dermatologic 
creams were selected by analysing the composition of 
excipients from different brands found in the Brazilian 
market, compared to the reference product (Zovirax®, 
GlaxoSmithKline). Table I presents the qualitative 
composition of chosen formulations according to excipient 
function or action within the formulation. Two medicines 
with similar formulations and one with a different 
composition were selected. R and G products present 
excipients with equivalent characteristics for instance, 
including propylene glycol, whose presence may promote 
drug permeation. In contrast, medicine S did not contain 
that inactive ingredient.
All reagents were analytical or HPLC grade. Ultra-
pure water was obtained by 3UV Millipore® Derect-Q 
(Molsheim, France). Pig ears were acquired from the Ouro 
do Sul slaughterhouse (Harmonia, Brazil).
Chromatographic system
The analytical method was developed in a Shimadzu 
LC-10A system (Kyoto, Japan) equipped with an LC-
20AT pump, SPD-20AV UV-VIS variable wavelength 
detector (254 nm), DGU-20A5 degasser, CBM-20A 
controller system, and SIL-20A injection valve with 100 
μL loop. Phenomenex C8 column (5 μm, 250 mm x 4.6 
mm i.d.) and pre column C8 (4 x 3.0 mm) were kept at 
25 °C. The mobile phase consisted of water and methanol 
(95:5, v/v) in isocratic mode, with 1 mL/min flow and 50 
µL of sample injection was used.
TABLE I - Qualitative composition of 5 % ACV creams selected (water and ACV are elements present in all formulations and 
therefore not included in this table
Product Preservative Emulsifier Lipophilic vehicle/Emollient
Absorption 
promoter Others
Glaxo SmithKline 
(Reference) -
Cetostearyl alcohol, 
polaxamer 407
Vaseline, liquid 
paraffin.
Propylene glycol Sodium lauril sulfate
Prati-Donaduzzi 
(Generic)
Propylparaben 
Methylparaben Cetostearyl alcohol Liquid petrolatum Propylene glycol Sodium lauril sulfate
Cimed (Similar) Propylparaben Methylparaben Emulsifying wax Yellow petrolatum - -
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Skin preparation
Pig ears, obtained before the slaughter line scalding 
step, were initially washed with water. The central portion 
of the external side was excised and cut with a scalpel and 
moulded into a round shape to fit Franz cells, wrapped 
with PVC film and aluminium foil and kept under -20 °C 
for up to 30 days.
Acyclovir extraction procedure
In order to validate the extraction procedure, skin 
segments without blood vessels or scars were cut in 1.5 
cm diameter circles (equivalent to the Franz cells contact 
area). For validation requirements, dermis and epidermis 
separation was performed with a scalpel after immersion 
into water at 60°C for 45 seconds. Dermis was additionally 
sectioned into small parts and, only then transferred to 
separate tubes. Dermis and epidermis were spiked with 
ACV aqueous solution and kept still for 2 hours. The cycle 
of ACV extraction from skin layers occurred by addition of 
4 mL of water in the tubes and sonication for over 40 min
Bioanalytical method validation
Bioanalytical method validation followed national 
and international guidelines (ANVISA, 2012; ICH, 
2005). Method specificity was evaluated by comparing 
chromatograms from samples with and without ACV after 
skin extraction. 
Standard curves were analysed on three different 
days with drug concentrations from 0.5 to 25 µg/mL. 
Samples were diluted with biological matrices in the same 
proportion as the extraction procedure (1.5 cm diameter 
skin per 8 mL of water). Results were submitted to linear 
regression analysis through minimum square method 
and ANOVA (analysis of variance) statistical evaluation. 
Limits of detection and quantification were estimated 
according to standard curve and confirmed through 
experiments. Intercept significance was also verified.
Method precision was assessed by ACV recovery 
from the main skin layers. After separation, dermis and 
epidermis were spiked with 50 µL of ACV solution at three 
known concentration levels (low, median, and high). The 
final concentration corresponded to 0.5, 12.5, and 25 µg/mL; 
each level had n = 6 for both skin layers.
In vitro skin penetration studies
Skin samples were thawed at room temperature 
and mounted in Franz diffusion cells (Hanson Research, 
Chatsworth, USA) with stratum corneum (SC) facing 
donor compartment and dermis in contact with receptor 
compartment. The diffusion area of Franz cells was 1.77 
cm2, and the receptor container was filled with 7 mL 
phosphate buffer, pH 7.4. Pig skin was kept in contact with 
the receptor solution at 32 °C (±1 °C) for up to 8 hours and 
aliquots of 1 mL were collected at predetermined times 
(1, 4, 6, and 8 h) to analyse ACV permeation through 
the skin. The same volume of receptor fluid withdrawn 
was replaced to keep it constant. After 8 hours, skin was 
detached from the Franz cell and excess formulation 
carefully removed. Without water immersion, scalpel and 
scissor were applied to separate skin layers, epidermis and 
dermis, which were weighed and extraction proceeded as 
described previously.
Results are presented as µg of ACV per mg of tissue; 
all data (n = 15) and mean values ± standard deviation (SD) 
were computed. Data were analysed by one-way ANOVA 
in order to compare the three pharmaceutical formulations. 
Tukey test was applied to significant results (α = 0.05).
Pharmacodynamic study – simulation of ACV 
antiviral effect on skin layers
Scientific literature provides different in vitro 
and in vivo values for inhibition of HSV-1 replication. 
Values of IC50 (inhibitory concentration for 50 % of viral 
replication) found for plaque number reduction assay 
using Vero cells presented divergent patterns, which, for 
the purpose of this study, were classified as low, median, 
and high potency, evidencing the characteristic of drug-
virus interaction (species-specific) (Cavalli et al., 2009; 
Drugbank databese; Gong et al., 2004; Jalón et al., 2003; 
Suzuki, Okuda, Shiraki, 2006).
Compar i son  be tween  expec ted  e ffec t s  a t 
concentration ranges found for ACV in the in vitro 
permeation assay from R, G, and S formulations was 
performed by means of Scientist® software program. 
employing a model of inhibitory effect for ACV and values 
of IC50 described in the literature for different viral strains 
(Table II). The model is described by equation 1, where 
E is the expected effect, E0 the effect on absence of drug 
inhibition, Imax is the maximum inhibition promoted by 
ACV (inhibition of replication), C is ACV concentration 
evaluable in the tissue to produce an effect (in this situation 
µg/g was employed), and IC50 (µg/mL) is the concentration 
necessary to promote half of the maximum inhibitory 
effect (Gabrielsson, Weiner, 2006).
  Equation 1
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To obtain a dose-response curve, low, median, and 
high IC50 (0.049, 0.265, and 0.850 µg/mL, respectively) 
values from scientific literature were used.
RESULTS AND DISCUSSION
Method validation
Analytical conditions allowed an adequate peak 
signal of ACV in the presence of biological matrix, 
although with small interferences. According to official 
regulation guidelines, the presence of a chromatographic 
response relative to blank sample along with analyte must 
be lower than 20 % of the limit of quantification (LoQ). 
On that basis, at the lower quantification concentration 
of ACV (0.5 µg/mL), the higher signal from biological 
matrices corresponded to 2.95 % and 11.75 % of the 
drug peak signal in epidermis and dermis, respectively 
(Figure 2).
The method developed presented an appropriate 
linearity at 0.5 – 25 µg/mL concentration range from 3 
days analysis. The mean standard curve equation y = 
153656x + 33034 had a determination coefficient (r2) equal 
TABLE II - ACV IC50 values found in scientific literature for 
distinct HSV-1 strains in plaque number reduction assay. 
ACV IC50 IC50 ACV (µg/mL)1 Reference
1.3 µM 0.293(M) Drug Bank
0.16 µM 0.036(L) Cavalli et al, 2009
0.85 µg/mL 0.850(H) Suzuki, Okuda and 
Shiraki 2006
1.06 µM 0.238(M) Jalón et al, 2003
0.28 µM 0.063(L) Gong et al, 2004
(H): high value IC50; (M) median value of IC50; (L) low value 
IC50. 1: data were standardized in µg/mL
FIGURE 2 - Specificity of chromatographic method for the analysis of ACV in skin layers. A) Epidermis; B) Dermis. Black line: 
blank sample (biological matrix); grey line: ACV solution at 12.5 mg/mL, eluting at 7.8 min retention time.
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to 0.9999. According to data obtained from ANOVA it is 
possible to ensure significant linear regression (Fcalculated 
= 37278.2 >> Fcritical = 8.53) without deviation from 
linearity (Fcalculated = 0.35 < Fcritical = 4.20). Limits of 
detection and quantification were 0.11 and 0.36 µg/mL, 
respectively. Experimentally, five injections at 0.3, 0.4, and 
0.5 µg/mL presented an RSD of 0.77 %, 1.26 %, and 2.20 
%, demonstrating that the proposed LoQ was precise and 
sensitive. During the study, every chromatographic run 
was performed with a new standard curve, which furnished 
an average slope of (n=18). The p-value for the intercept 
was always greater than 0.05. 
Method precision and accuracy were evaluated 
in terms of ACV recovery from biological matrices. 
Table III presents data obtained for ACV recovery 
from skin layers (epidermis and dermis), and RSD for 
intra-day repeatability and intermediate precision at 
each concentration level of ACV added to matrices. 
Average data recovered were 92.74% for epidermis and 
90.65% for dermis, values which are in agreement with 
those recommended by scientific guidelines. Regarding 
precision assessment, RSD ranged from 4.36 % to 6.77 % 
which is considered acceptable for a bioanalytical method 
(<15 %) and also indicates suitability of the extraction 
process and quantification of ACV in the main skin layers.
Comparative cutaneous penetration study
A validated bioanalytical method was applied to 
the quantification of ACV in both skin layers (dermis 
and epidermis) after formulations were applied. ACV 
penetration was evaluated from three commercial creams 
(R, G, and S) in two different batches, corresponding 
to six samples. Results regarding accumulated amount 
of ACV in skin layers for R, G, and S samples in a 
cutaneous permeation study are shown in Figures 3 
and 4. Evaluating Figure 3, it can be concluded that 
overall, a higher concentration of ACV is detected in 
epidermis than in dermis, a condition that is ideal for ACV 
pharmacological effect against herpes virus. The amount 
of drug accumulated in epidermis and dermis for R and S 
products was substantially lower than that obtained with 
G, according to statistical evaluation. The main difference 
between the formulations is the presence of propylene 
glycol in the R and G products. This excipient may have 
more than one function in a pharmaceutical formulation. 
Besides being a carrier, it can act as permeation promoter 
in amounts usually applied for dermatological products 
(Trottet et al., 2004). The action mechanism proposed for 
propylene glycol suggests that its input in SC increases 
penetrant solubility, with a consequent increment of the 
flow through skin tissue (Moser et al., 2001; Williams, 
TABLE III - Accuracy and precision of the bioanalytical method for ACV quantification
Skin Layers Level
Day 1 Day 2
Observed 
concentration ± SD 
RSD (%) 
intra-day
Observed 
concentration ± SD
RSD (%) 
intra-day
RSD (%) 
inter-day
Epidermis
Low 0.42 ± 0.02 4.92 0.43 ± 0.02 4.65 4.36
Medium 11.82 ± 0.9 7.54 12.83 ± 0.05 0.36 6.41
High 22.41 ± 1.50 6.72 24.46 ± 0.24 0.99 6.32
Dermis
Low 0.47 ± 0.01 3.27 0.48 ± 0.04 7.94 5.6
Medium 10.95 ± 1.2 10.33 11.35 ± 0.16 1.38 6.77
High 22.15 ± 2.0 9.05 21.96 ± 0.70 3.17 6.10
FIGURE 3 - Retained amount of ACV in porcine skin layers 
regarding the first batch of reference (R), generic (G), and similar 
(S) products, expressed in µg/mg. Each symbol corresponds to 
an obtained value and the horizontal bar represents the mean 
concentration (n = 15).
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Barry, 2012). The manufacturers do not inform the amount 
of propylene glycol, but it is possible that one of those 
mechanisms occurred, explaining the higher concentration 
of ACV from the first batch of G product found in skin 
layers.
Another difference that can be considered is the 
presence of sodium lauryl sulfate (SLS - anionic surfactant) 
in R and G formulations. The action mechanism of SLS 
has not yet been completely explained. However, it is well 
known that it interacts with keratin and intracellular lipids, 
and also promotes changes in the helix conformation of 
SC proteins, facilitating drug absorption (Nokhodchi et 
al., 2003; Rafeiro, 2013). Therefore, this characteristic 
will differ between formulations, according to the 
concentration of SLS.
It  should be highlighted that  physical  and 
physicochemical characteristics of the drug and further 
elements in the formulation, as well as in the manufacturing 
process, may lead to variation of bioavailability that, for 
the generic product, may compromise bioequivalence and, 
therefore inter-changeability. Product R presented higher 
viscosity than products G and S, which supplied very 
similar rheological profiles (data not shown).
On the other hand, statistical evaluation of the 
second batch (Figure 4) has indicated the absence of a 
significant difference (p>0.05) between formulations R, 
G, and S. Dissimilar results regarding batches 1 and 2 for 
G product may indicate the poor homogeneity between 
manufactured batches. Semi solid pharmaceutical dosage 
forms are complex formulations and their physicochemical 
release and penetration properties involve several factors. 
Initial separation of the system into two phases and the 
step of adding an active component are critical points in 
the semisolid fabrication process. Any change in one of 
these processes may alter the formulation properties, and 
the permeation and release characteristics of the active 
ingredient (OECD, 2004).
A statistical analysis performed between batches 
(for the same brand) pointed out the homogeneity of ACV 
retained in the epidermis for formulation R, but a different 
retention in the dermis. This also occurred for product G 
(epidermis: p = 0.539 and dermis: p = 0.009), while for 
product S, the retained amount in epidermis (p = 0.206) 
was considered equal comparing the two lots, as well as 
in dermis (p = 0.06). 
As for the sum of ACV amounts retained in both 
layers, statistical tests showed no significant difference 
between the batches of pharmaceutical products (Figure 
5). Statistical analysis of overall assessments (comparison 
between two lots of three products) revealed a significant 
difference only between R product from the second batch 
and G product from the first batch.
Whenever cutaneous permeation/penetration 
was evaluated (8 h), ACV was not detected in the 
receptor solution. According to Hasler-Nguyen et al. 
(2009) ACV presents a hydrophobic region which can 
interact with the hydrophobic structures in SC, affecting 
drug permeation. On the other hands, dermis presents 
hydrophilic characteristics thereby representing a barrier 
against free transition of substances with high partition 
coefficient and limited water solubility. These results 
confirm the release of ACV only in skin tissue (topically), 
which is the location required for effective treatment of 
FIGURE 4 - Retained amount of ACV in porcine skin layers 
regarding the second batch of reference (R), generic (G), 
and similar (S) products, expressed in µg/mg. Each symbol 
corresponds to an obtained value and the horizontal bar 
represents the mean concentration (n = 15).
FIGURE 5 - Retained amount of ACV from reference (R), generic 
(G), and similar (S) products with the drug concentrations found 
in skin layers (epidermis + dermis) for the two batches analysed.
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cutaneous herpetic viruses, without achieving systemic 
circulation and causing adverse effects.
It is worth noting that high values obtained for 
standard deviation during experiments performed can be 
explained by inherent variability by the inherent variability 
of studies with characteristics from cutaneous tissue (pig 
skin) – interindividual differences, growth, sex, and skin 
thickness (Godin, Touitou, 2007). Those values might be 
related to skin layer weight which was fairly uniform: 
22.2 ± 6.7 mg for epidermis and 92.0 ± 23.7 mg for dermis 
over ninety measurements (Table IV).
Recently, the national drug regulation agency of 
Brazil (ANVISA, 2014) declared that eleven topical 
brands of ACV were interchangeable, including the 
products employed in this study. In the USA, the FDA 
determines the optimal bioequivalence approach for 
each proposed generic topical formulation on a case-
by-case basis. The approach may be pharmacokinetics, 
pharmacodynamics, clinical or in vitro considering drug 
mechanism and site of action, complexity of reference 
formulation, and feasibility and sensitivity of each 
approach. For ACV ointment 5%, generic and reference 
products must contain the same amounts of active and 
inactive ingredients and, as in the USA, the reference is 
considerably less complex than a cream, consisting of 
drug suspended in a polyethylene glycol (PEG) base. The 
in vitro release approach (with inert membrane) can be 
used for equivalence purposes. Particle size, viscosity, 
morphic form and PEG molecular weight distribution are 
also required. No cutaneous permeation is mentioned in 
the document. The products employed in this study are 
creams and ACV release through synthetic membrane was 
not evaluated (Davit, 2013).
Simulation of viral inhibitory effect on skin layers
When a pharmacodynamics study is performed, a 
direct relationship is expected between exposition and 
effect, and thus higher drug exposition will result in an 
increased viral inhibition response.
Results show that concentrations achieved for ACV 
in total skin, for all pharmaceutical specialities studied 
and two batches analysed would present an antiviral effect 
that is much superior to 50 % of inhibition. Therefore, 
studied products may be considered capable of providing 
ACV in cutaneous tissue in amounts that surpass IC50 viral 
replication, even when there are strains with high IC50 
values. Throughout the drug concentration range found in 
the skin tissue, the effect calculated according to Equation 
1 was greater than 98%. Therefore, medicines evaluable in 
the Brazilian market are believed to present an adequate 
therapeutic effect against herpes virus, and are capable of 
shortening the viral cycle and reducing the main symptoms 
(rash, burn, and redness).
CONCLUSION
The proposed analytical methodology is sensitive, 
accurate and precise for the detection and quantification of 
ACV in skin layers of pig ears and therefore, in accordance 
TABLE IV - Medium and Standard deviation (SD) from 15 determinations regarding the penetration study in porcine skin for the 
analyzed batch
Commercial Creams Batch Skin Layers* Medium (µg/mg)** Standard deviation – SD (µg/mg)
R
1
E 0.60 0.34
D 0.25 0.10
2
E 0.62 0.42
D 0.12 0.06
G
1
E 1.09 0.49
D 0.47 0.20
2
E 0.94 0.76
D 0.30 0.36
S
1
E 0.70 0.37
D 0.18 0.08
2
E 0.97 0.73
D 0.26 0.15
*E= epidermis; D= dermis; **n=15
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with national and international standards. According to 
the studies performed the different composition with 
absence of propylene glycol in S product is not evidenced 
by means of an in vitro cutaneous penetration test and 
it can be assumed that the method possesses a limited 
capability to distinguish some differences in formulations 
due to its inherent variability. The results obtained for 
the ACV amounts in the skin are in accordance with the 
interchangeability between products proposed by the 
national regulatory agency for medicines. Nevertheless, 
it may be important to evaluate drug skin absorption from 
semisolid formulations during the development phase, as 
well as to predict drug concentration in skin layers (dermis 
and epidermis).
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